Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001564590-22-019261
Filing Date
2022-05-10
Accepted
2022-05-10 16:02:01
Documents
67
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 6-K frln-6k_20220510.htm   iXBRL 6-K 1789076
2 EX-99.1 frln-ex991_6.htm EX-99.1 217485
3 GRAPHIC gm4htmcwfgxk000001.jpg GRAPHIC 2136
  Complete submission text file 0001564590-22-019261.txt   6644238

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA frln-20220510.xsd EX-101.SCH 50651
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE frln-20220510_cal.xml EX-101.CAL 49622
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE frln-20220510_def.xml EX-101.DEF 160118
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE frln-20220510_lab.xml EX-101.LAB 360711
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE frln-20220510_pre.xml EX-101.PRE 289323
61 EXTRACTED XBRL INSTANCE DOCUMENT frln-6k_20220510_htm.xml XML 1081637
Mailing Address STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE X0 SG1 2FX
Business Address STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE X0 SG1 2FX 44 (0)1438 906870
Freeline Therapeutics Holdings plc (Filer) CIK: 0001810031 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39431 | Film No.: 22909432
SIC: 2836 Biological Products, (No Diagnostic Substances)